Syk

亜型選択性的な製品

シグナル伝達経路

Sykシグナル伝達経路

Syk製品

  • All (22)
  • Syk阻害剤 (22)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S2194 R406 R406(R406 besylate) is a potent Syk inhibitor with IC50 of 41 nM in cell-free assays, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. R406 induces apoptosis. Phase 1.
Cell Mol Immunol, 2023, 1-14.
Cancer Res, 2023, 83(2):316-331
Front Immunol, 2023, 14:1108244
S1533 R406 (free base) R406 (free base) is a potent Syk inhibitor with IC50 of 41 nM in a cell-free assay, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. R406 (free base) triggers apoptosis. Phase 1.
Cancer Res, 2023, 83(2):316-331
Life Sci Alliance, 2023, 6(11)e202302106
Theranostics, 2022, 12(5):2232-2247
S8032 PRT062607 (P505-15) HCl PRT062607 (P505-15, BIIB057, PRT-2607) is a novel, highly selective Syk inhibitor with IC50 of 1 nM in cell-free assays, >80-fold selective for Syk than Fgr, PAK5, Lyn, FAK, Pyk2, FLT3, MLK1 and Zap70.
J Exp Med, 2023, 220(9)e20230054
Adv Sci (Weinh), 2023, 10(10):e2205397
J Thromb Haemost, 2023, 21(8):2236-2247
S7523 Entospletinib (GS-9973) Entospletinib (GS-9973) is an orally bioavailable, selective Syk inhibitor with IC50 of 7.7 nM in a cell-free assay and showed 13- to >1000-fold cellular selectivity for Syk over other kinases(including Jak2, ckit, Flt3, Ret, KDR) as assessed by target protein phosphorylation or functional response.
Cancer Res, 2023, 83(2):316-331
Front Immunol, 2023, 14:1279155
J Leukoc Biol, 2023, qiad025
S2625 Fostamatinib (R788) Fostamatinib (R788), a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 3.
J Exp Med, 2023, 220(9)e20230054
Cancer Res, 2023, 83(16):2675-2689
Res Sq, 2023, rs.3.rs-2922520
S3026 Piceatannol Piceatannol, a natural stilbene, is a selective Syk inhibitor and ~10-fold selectivity versus Lyn.
ACS Appl Mater Interfaces, 2022, 14(21):24144-24159
Sci China Life Sci, 2022, 10.1007/s11427-022-2185-9
Cell Rep, 2022, 38(13):110567
S7634 Cerdulatinib (PRT062070) hydrochloride Cerdulatinib (PRT-062070, PRT2070) hydrochloride is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.
Int J Mol Sci, 2023, 24(17)13623
Cells, 2023, 12(3)453
Cancer Cell, 2022, S1535-6108(22)00312-9
S2206 Fostamatinib (R788) disodium Fostamatinib disodium (R788, Tamatinib Fosdium), a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM in a cell-free assay, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 3.
Cancer Res, 2023, 83(16):2675-2689
Int J Hematol, 2022, 10.1007/s12185-021-03220-9
J Allergy Clin Immunol, 2021, S0091-6749(21)00979-9
S7006 BAY-61-3606 BAY-61-3606 is a potent and selective inhibitor of Syk kinase (Ki = 7.5 nM). BAY-61-3606 induces cell cycle arrest and apoptosis.
Open Life Sci, 2023, 18(1):20220678
Nat Commun, 2022, 13(1):6226
Nat Commun, 2022, 13(1):6226
S7738 PRT-060318 2HCl PRT-060318 (PRT318) is a novel selective inhibitor of the Syk tyrosine kinase, as an approach to HIT treatment.
PLoS Pathog, 2022, 18(4):e1010468
FASEB J, 2020, 34(11):15208-15221
Cell Commun Signal, 2019, 17(1):122
S3566 Cerdulatinib (PRT062070) Cerdulatinib (PRT062070, PRT2070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively, also inhibits19 other tested kinases with IC50 less than 200 nM.
Int J Mol Sci, 2023, 24(17)13623
Cells, 2023, 12(9)1295
Cells, 2023, 12(9)1295
S8442 TAK-659 TAK-659 is a potent and selective inhibitor of spleen tyrosine kinase (SYK) with an IC50 value of 3.2 nM. It is selective against most other kinases, but potent toward both SYK and FLT3.
Int J Mol Sci, 2022, 23(23)14706
Am J Physiol Cell Physiol, 2021, 320(5):C902-C915
ScholarsArchive@OSU, 2020, 51
S4921 MNS (3,4-Methylenedioxy-β-nitrostyrene) MNS is a tyrosine kinase inhibitor, inhibits Syk, Src, p97 with IC50 of 2.5 μM, 29.3 μM and 1.7 μM, respectively.
Phytomedicine, 2019, 61:152859
J Biomol Struct Dyn, 2019, 10.1080/07391102.2019.1640133
Toxicol Res (Camb), 2016, 5(1):188-196
S4944 Fostamatinib disodium hexahydrate Fostamatinib (R788) disodium (Tamatinib Fosdium) hexahydrate, a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM in a cell-free assay.
Int J Hematol, 2022, 10.1007/s12185-021-03220-9
J Allergy Clin Immunol, 2021, S0091-6749(21)00979-9
ScholarsArchive@OSU, 2020, None
S7286 RO9021 RO9021 potently inhibits SYK kinase activity with an average IC50 of 5.6 nM and suppresses B-cell receptor signaling.
Int J Mol Sci, 2022, 23(23)14706
S6519 R112 R112 is an ATP-competitive spleen tyrosine kinase (Syk) inhibitor with Ki value of 96 nM.
S3226 Dehydroabietic acid Dehydroabietic acid (DAA, DHAA), a naturally occurring diterpene resin acid derived from coniferous plants such as Pinus and Picea, displays anti-inflammatory activity via suppression of Src-, Syk-, and TAK1-mediated pathways.
S0871 Gusacitinib (ASN-002) Gusacitinib (ASN-002) is a novel and potent dual inhibitor of spleen tyrosine kinase (SYK) and Janus kinases (JAK) with IC50 values of 5-46 nM in biochemical assays.
S9715 Lanraplenib (GS-SYK) Lanraplenib (GS-SYK) is a potent, highly selective and orally active inhibitor of Spleen Tyrosine Kinase (SYK) with IC50 of 9.5 nM. Lanraplenib inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
S8948 SRX3207 SRX3207 is an orally active dual inhibitor of Syk-PI3K with IC50 of 39.9 nM, 31200 nM, 3070 nM, 3070 nM, 244 nM, 388 nM, 9790 nM for Syk, Zap70, BRD41, BRD42, PI3K alpha, PI3K delta, PI3K gamma, respectively. SRX3207 blocks tumor immunosuppression and increases anti-tumor immunity.
E0437New ZAP-180013 ZAP-180013 is a inhibitor of zeta-chain-associated protein kinase 70 (ZAP-70) with an IC50 of 1.8 μM.
E4580New Sovleplenib Sovleplenib(HMPL-523) is a highly potent and selective SYK inhibitor with IC50 of 0.025 μM, that exhibits anti-tumor activities in vitro and in vivo. Sovleplenib exhibits synergistic activities in combination with BTK, PI3Kδ, and Bcl2 family inhibitors in killing human-diffused large B cell lymphoma (DLBCL).
S2194 R406 R406(R406 besylate) is a potent Syk inhibitor with IC50 of 41 nM in cell-free assays, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. R406 induces apoptosis. Phase 1.
Cell Mol Immunol, 2023, 1-14.
Cancer Res, 2023, 83(2):316-331
Front Immunol, 2023, 14:1108244
S1533 R406 (free base) R406 (free base) is a potent Syk inhibitor with IC50 of 41 nM in a cell-free assay, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. R406 (free base) triggers apoptosis. Phase 1.
Cancer Res, 2023, 83(2):316-331
Life Sci Alliance, 2023, 6(11)e202302106
Theranostics, 2022, 12(5):2232-2247
S8032 PRT062607 (P505-15) HCl PRT062607 (P505-15, BIIB057, PRT-2607) is a novel, highly selective Syk inhibitor with IC50 of 1 nM in cell-free assays, >80-fold selective for Syk than Fgr, PAK5, Lyn, FAK, Pyk2, FLT3, MLK1 and Zap70.
J Exp Med, 2023, 220(9)e20230054
Adv Sci (Weinh), 2023, 10(10):e2205397
J Thromb Haemost, 2023, 21(8):2236-2247
S7523 Entospletinib (GS-9973) Entospletinib (GS-9973) is an orally bioavailable, selective Syk inhibitor with IC50 of 7.7 nM in a cell-free assay and showed 13- to >1000-fold cellular selectivity for Syk over other kinases(including Jak2, ckit, Flt3, Ret, KDR) as assessed by target protein phosphorylation or functional response.
Cancer Res, 2023, 83(2):316-331
Front Immunol, 2023, 14:1279155
J Leukoc Biol, 2023, qiad025
S2625 Fostamatinib (R788) Fostamatinib (R788), a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 3.
J Exp Med, 2023, 220(9)e20230054
Cancer Res, 2023, 83(16):2675-2689
Res Sq, 2023, rs.3.rs-2922520
S3026 Piceatannol Piceatannol, a natural stilbene, is a selective Syk inhibitor and ~10-fold selectivity versus Lyn.
ACS Appl Mater Interfaces, 2022, 14(21):24144-24159
Sci China Life Sci, 2022, 10.1007/s11427-022-2185-9
Cell Rep, 2022, 38(13):110567
S7634 Cerdulatinib (PRT062070) hydrochloride Cerdulatinib (PRT-062070, PRT2070) hydrochloride is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.
Int J Mol Sci, 2023, 24(17)13623
Cells, 2023, 12(3)453
Cancer Cell, 2022, S1535-6108(22)00312-9
S2206 Fostamatinib (R788) disodium Fostamatinib disodium (R788, Tamatinib Fosdium), a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM in a cell-free assay, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 3.
Cancer Res, 2023, 83(16):2675-2689
Int J Hematol, 2022, 10.1007/s12185-021-03220-9
J Allergy Clin Immunol, 2021, S0091-6749(21)00979-9
S7006 BAY-61-3606 BAY-61-3606 is a potent and selective inhibitor of Syk kinase (Ki = 7.5 nM). BAY-61-3606 induces cell cycle arrest and apoptosis.
Open Life Sci, 2023, 18(1):20220678
Nat Commun, 2022, 13(1):6226
Nat Commun, 2022, 13(1):6226
S7738 PRT-060318 2HCl PRT-060318 (PRT318) is a novel selective inhibitor of the Syk tyrosine kinase, as an approach to HIT treatment.
PLoS Pathog, 2022, 18(4):e1010468
FASEB J, 2020, 34(11):15208-15221
Cell Commun Signal, 2019, 17(1):122
S3566 Cerdulatinib (PRT062070) Cerdulatinib (PRT062070, PRT2070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively, also inhibits19 other tested kinases with IC50 less than 200 nM.
Int J Mol Sci, 2023, 24(17)13623
Cells, 2023, 12(9)1295
Cells, 2023, 12(9)1295
S8442 TAK-659 TAK-659 is a potent and selective inhibitor of spleen tyrosine kinase (SYK) with an IC50 value of 3.2 nM. It is selective against most other kinases, but potent toward both SYK and FLT3.
Int J Mol Sci, 2022, 23(23)14706
Am J Physiol Cell Physiol, 2021, 320(5):C902-C915
ScholarsArchive@OSU, 2020, 51
S4921 MNS (3,4-Methylenedioxy-β-nitrostyrene) MNS is a tyrosine kinase inhibitor, inhibits Syk, Src, p97 with IC50 of 2.5 μM, 29.3 μM and 1.7 μM, respectively.
Phytomedicine, 2019, 61:152859
J Biomol Struct Dyn, 2019, 10.1080/07391102.2019.1640133
Toxicol Res (Camb), 2016, 5(1):188-196
S4944 Fostamatinib disodium hexahydrate Fostamatinib (R788) disodium (Tamatinib Fosdium) hexahydrate, a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM in a cell-free assay.
Int J Hematol, 2022, 10.1007/s12185-021-03220-9
J Allergy Clin Immunol, 2021, S0091-6749(21)00979-9
ScholarsArchive@OSU, 2020, None
S7286 RO9021 RO9021 potently inhibits SYK kinase activity with an average IC50 of 5.6 nM and suppresses B-cell receptor signaling.
Int J Mol Sci, 2022, 23(23)14706
S6519 R112 R112 is an ATP-competitive spleen tyrosine kinase (Syk) inhibitor with Ki value of 96 nM.
S3226 Dehydroabietic acid Dehydroabietic acid (DAA, DHAA), a naturally occurring diterpene resin acid derived from coniferous plants such as Pinus and Picea, displays anti-inflammatory activity via suppression of Src-, Syk-, and TAK1-mediated pathways.
S0871 Gusacitinib (ASN-002) Gusacitinib (ASN-002) is a novel and potent dual inhibitor of spleen tyrosine kinase (SYK) and Janus kinases (JAK) with IC50 values of 5-46 nM in biochemical assays.
S9715 Lanraplenib (GS-SYK) Lanraplenib (GS-SYK) is a potent, highly selective and orally active inhibitor of Spleen Tyrosine Kinase (SYK) with IC50 of 9.5 nM. Lanraplenib inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
S8948 SRX3207 SRX3207 is an orally active dual inhibitor of Syk-PI3K with IC50 of 39.9 nM, 31200 nM, 3070 nM, 3070 nM, 244 nM, 388 nM, 9790 nM for Syk, Zap70, BRD41, BRD42, PI3K alpha, PI3K delta, PI3K gamma, respectively. SRX3207 blocks tumor immunosuppression and increases anti-tumor immunity.
E0437New ZAP-180013 ZAP-180013 is a inhibitor of zeta-chain-associated protein kinase 70 (ZAP-70) with an IC50 of 1.8 μM.
E4580New Sovleplenib Sovleplenib(HMPL-523) is a highly potent and selective SYK inhibitor with IC50 of 0.025 μM, that exhibits anti-tumor activities in vitro and in vivo. Sovleplenib exhibits synergistic activities in combination with BTK, PI3Kδ, and Bcl2 family inhibitors in killing human-diffused large B cell lymphoma (DLBCL).
E0437New ZAP-180013 ZAP-180013 is a inhibitor of zeta-chain-associated protein kinase 70 (ZAP-70) with an IC50 of 1.8 μM.
E4580New Sovleplenib Sovleplenib(HMPL-523) is a highly potent and selective SYK inhibitor with IC50 of 0.025 μM, that exhibits anti-tumor activities in vitro and in vivo. Sovleplenib exhibits synergistic activities in combination with BTK, PI3Kδ, and Bcl2 family inhibitors in killing human-diffused large B cell lymphoma (DLBCL).

Syk阻害剤の選択性比較

Tags: Syk inhibition | Syk signaling | Syk pathway | Syk activation | Syk cancer | Syk phosphorylation | Syk inhibitors in development | Syk signaling pathway | spleen tyrosine kinase pathway | Syk inhibitor review